Adrenal adenomas: what to do with them? Review 2

Main Article Content

S. Rybakov

Abstract

Adrenal incidentalomas (AI) are a collective, working category that contains a wide range of different forms of patho­logy of these glands. They differ in the original tissue structures from which they originate, in clinical and hormonal characte­ristics, in diagnostic and tactical approaches. Such a wide range of emergencies, which are hidden under the guise of accidentally detected AI, puts before the clinician the task of identifying them (establishing a clinical and, if possible, morphological diagnosis) with the definition of tactical approaches. Based on the analysis of these data, as well as numerous publications, their working classification is proposed. When deciding on surgical treatment, the surgeon must have a clinical diagnosis — what nosological form of adrenal pathology is to be operated on. Interventions with the diagnosis AI are unacceptable and are a gross error. The optimal operation for most such tumors is laparoscopic adrenalectomy with the tumor. Open operations are indicated for malignant tumors of significant size, especially with signs of invasion into surrounding structures. Given that most AI are benign formations, it is equally important to determine further tactics for them — the mode and duration of observation, the order and scope of control clinical and hormonal and imaging studies, the principles of evaluation of the results. Several guidelines indicate that in the presence of hormonally inactive adenomas, without signs of malignancy, less than 3–4 cm in size, no further observation is indicated. It is noted that in such tumors the tendency to growth, malignancy, emergence of hormonal activity is extremely seldom observed. In other cases, especially with the slightest doubt of the initial results, follow-up examinations are recommended after 3, 6, 12 months and then after 1–2 years, the maxi­mum period is set to five years. These parameters are the subject of discussion in various clinics.

Article Details

How to Cite
Rybakov, S. “Adrenal Adenomas: What to Do With Them? Review 2”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 3, June 2021, pp. 241-9, doi:10.22141/2224-0721.17.3.2021.232655.
Section
Literature Review

References

Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi:10.1530/EJE-16-0467.

Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal Incidentaloma. Endocr Rev. 2020 Dec 1;41(6):775-820. doi:10.1210/endrev/bnaa008.

Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000 Feb;85(2):637-644. doi:10.1210/jcem.85.2.6372.

Ichijo T, Ueshiba H, Nawata H, Yanase T. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J. 2020 Feb 28;67(2):141-152. doi:10.1507/endocrj.EJ18-0486.

Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008 May;190(5):1163-1168. doi:10.2214/AJR.07.2799.

Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003 Oct;149(4):273-285. doi:10.1530/eje.0.1490273.

Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004 Apr;25(2):309-340. doi:10.1210/er.2002-0031.

Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011 Jun;164(6):851-870. doi:10.1530/EJE-10-1147.

Kim J, Bae KH, Choi YK, et al. Clinical characteristics for 348 patients with adrenal incidentaloma. Endocrinol Metab (Seoul). 2013 Mar;28(1):20-25. doi:10.3803/EnM.2013.28.1.20.

Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007 Feb 8;356(6):601-610. doi:10.1056/NEJMcp065470.

Reimondo G, Castellano E, Grosso M, et al. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz284. doi:10.1210/clinem/dgz284.

Arruda M, Mello Ribeiro Cavalari E, Pessoa de Paula M, et al. The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test. J Hum Hypertens. 2017 Dec;32(1):3-11. doi:10.1038/s41371-017-0011-4.

Schaaf WE Jr, Patel Z, Retrouvey M, Cunningham TD, Johnson LS. Frequency and clinical relevance of PET/CT incidentalomas. Abdom Imaging. 2014 Jun;39(3):657-662. doi:10.1007/s00261-014-0086-0.

NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements. 2002 Feb 4-6;19(2):1-25.

Zeiger MA, Thompson GB, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract. 2009 Jul-Aug;15(5):450-453. doi:10.4158/EP.15.5.450.

Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab. 2010 Sep;95(9):4106-4113. doi:10.1210/jc.2010-0457.

Bednarczuk T, Bolanowski M, Sworczak K, et al. Adrenal incidentaloma in adults - management recommendations by the Polish Society of Endocrinology. Endokrynol Pol. 2016;67(2):234-258. doi:10.5603/EP.a2016.0039.

Sahdev A. Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists? Br J Radiol. 2017 Apr;90(1072):20160627. doi:10.1259/bjr.20160627.

Gendy R, Rashid P. Incidental adrenal masses - a primary care approach. Aust Fam Physician. 2017 Jun;46(6):385-390.

Thomas AZ, Blute ML Sr, Seitz C, Habra MA, Karam JA. Management of the Incidental Adrenal Mass. Eur Urol Focus. 2016 Feb;1(3):223-230. doi:10.1016/j.euf.2015.12.006.

Lee JM, Kim MK, Ko SH, et al. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017 Jun;32(2):200-218. doi:10.3803/EnM.2017.32.2.200.

Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006 Apr;29(4):298-302. doi:10.1007/BF03344099.

Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009 Oct;161(4):513-527. doi:10.1530/EJE-09-0234.

Beierwaltes WH, Sturman MF, Ryo U, Ice RD. Imaging functional nodules of the adrenal glands with 131-I-19-iodocholesterol. J Nucl Med. 1974 Apr;15(4):246-251.

Charbonnel B, Chatal JF, Ozanne P. Does the corticoadrenal adenoma with "pre-Cushing's syndrome" exist? J Nucl Med. 1981 Dec;22(12):1059-1061.

Nieman LK. Update on subclinical Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes. 2015 Jun;22(3):180-184. doi:10.1097/MED.0000000000000159.

Vilela LAP, Almeida MQ. Diagnosis and management of primary aldosteronism. Arch Endocrinol Metab. 2017 May-Jun;61(3):305-312. doi:10.1590/2359-3997000000274.

Byrd JB, Turcu AF, Auchus RJ. Primary Aldosteronism: Practical Approach to Diagnosis and Management. Circulation. 2018 Aug 21;138(8):823-835. doi:10.1161/CIRCULATIONAHA.118.033597.

Ng VW, Ma RC, So WY, et al. Evaluation of functional and malignant adrenal incidentalomas. Arch Intern Med. 2010 Dec 13;170(22):2017-2020. doi:10.1001/archinternmed.2010.441.

Pappachan JM, Raskauskiene D, Sriraman R, Edavalath M, Hanna FW. Diagnosis and management of pheochromocytoma: a practical guide to clinicians. Curr Hypertens Rep. 2014 Jul;16(7):442. doi:10.1007/s11906-014-0442-z.

Tsirlin A, Oo Y, Sharma R, Kansara A, Gliwa A, Banerji MA. Pheochromocytoma: a review. Maturitas. 2014 Mar;77(3):229-238. doi:10.1016/j.maturitas.2013.12.009.

Kahramangil B, Kose E, Remer EM, et al. A modern assessment of cancer risk in adrenal incidentalomas: analysis of 2219 patients. Ann Surg. 2020 Jun 11. doi:10.1097/SLA.0000000000004048.

Vural V, Kılınç EM, Sarıdemir D, et al. Association between Tumor Size and Malignancy Risk in Hormonally Inactive Adrenal Incidentalomas. Cureus. 2020 Jan 6;12(1):e6574. doi:10.7759/cureus.6574.